Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel for Craniofacial Pain
NCT04930887Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Feb 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupivacaine extended release liposome injection in Craniofacial pain, migraine, Cluster Headache (CH) and 3 more (2 arms), sponsored by Stanford University. Primary endpoint: Change of Pain at day 21. Started Feb 2023; status: recruiting.
02
Drugs
bupivacaine extended release liposome injection
03
Conditions
Craniofacial painmigraineCluster Headache (CH)trigeminal autonomic cephalalgias (TAC)Sphenopalatine ganglion neuralgia (SPG)
Beyond the preview
Go deeper on NCT04930887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930887.